These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 3457984)

  • 1. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
    [No Abstract]   [Full Text] [Related]  

  • 2. Changes in bone histology after treatment with desferrioxamine.
    Ott SM; Andress DL; Nebeker HG; Milliner DS; Maloney NA; Coburn JW; Sherrard DJ
    Kidney Int Suppl; 1986 Feb; 18():S108-13. PubMed ID: 3457986
    [No Abstract]   [Full Text] [Related]  

  • 3. [Osteomalacia induced by aluminum in a patient under chronic hemodialysis: successful treatment with desferrioxamine].
    Espinoza O; Gehrung E; Roessler E; Katz E; Pérez A; Delmastro J
    Rev Med Chil; 1986 Sep; 114(9):867-71. PubMed ID: 3575972
    [No Abstract]   [Full Text] [Related]  

  • 4. Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH.
    Nebeker HG; Andress DL; Milliner DS; Ott SM; Alfrey AC; Slatopolsky EA; Sherrard DJ; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S96-9. PubMed ID: 3458006
    [No Abstract]   [Full Text] [Related]  

  • 5. Aluminum intoxication of bone in renal failure--fact or fiction?
    Malluche HH; Faugere MC; Smith AJ; Friedler RM
    Kidney Int Suppl; 1986 Feb; 18():S70-3. PubMed ID: 3458000
    [No Abstract]   [Full Text] [Related]  

  • 6. [Aluminum-induced osteomalacia in chronic hemodialysis].
    Smetana S; Popovtzer MM; Bar-Khayim Y
    Harefuah; 1987 Jun; 112(12):595-7. PubMed ID: 3428727
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical and biochemical features of aluminum-related bone disease.
    Ihle BU; Becker GJ; Kincaid-Smith PS
    Kidney Int Suppl; 1986 Feb; 18():S80-6. PubMed ID: 3458003
    [No Abstract]   [Full Text] [Related]  

  • 8. [Toxic effect of aluminum in chronic renal failure].
    Głuszek J
    Pol Tyg Lek; 1987 Nov; 42(48):1499-502. PubMed ID: 3451199
    [No Abstract]   [Full Text] [Related]  

  • 9. Aluminum in chronic hemodialysis. Possible influence on osteomalacic bone disease.
    Quarello F; Giachino G; Bossi P; Gilli G; Corrao G; Scursatone E; Jeantet A; Bossi R; Coppo R; Piccoli G; Vercellone A
    Minerva Nefrol; 1980; 27(4):635-44. PubMed ID: 7254691
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of plasma aluminum in the detection and prevention of aluminum toxicity.
    Winney RJ; Cowie JF; Robson JS
    Kidney Int Suppl; 1986 Feb; 18():S91-5. PubMed ID: 3458005
    [No Abstract]   [Full Text] [Related]  

  • 11. Fracture healing with deferoxamine therapy in a patient with aluminum-associated osteomalacia.
    Phelps KR; Einhorn TA; Vigorita VJ; Lundin AP; Friedman EA
    ASAIO Trans; 1986; 32(1):198-200. PubMed ID: 3778712
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapy of aluminum overload (I).
    Pierides AM; Myli MP
    Contrib Nephrol; 1984; 38():65-77. PubMed ID: 6425013
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapy of aluminium overload (II).
    Ackrill P; Day JP
    Contrib Nephrol; 1984; 38():78-80. PubMed ID: 6713902
    [No Abstract]   [Full Text] [Related]  

  • 14. Aluminum-related osteomalacia: clinical and histological improvement following treatment with desferrioxamine (DFO).
    Rapoport J; Chaimovitz C; Abulfil A; Mostovlavsky M; Gazit D; Bab I
    Isr J Med Sci; 1987 Dec; 23(12):1242-6. PubMed ID: 3440748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteomalacia and bone disease arising from aluminum.
    Coburn JW; Norris KC; Nebeker HG
    Semin Nephrol; 1986 Mar; 6(1):68-89. PubMed ID: 3110896
    [No Abstract]   [Full Text] [Related]  

  • 16. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM
    Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of desferrioxamine in the treatment of dialysis encephalopathy.
    Ackrill P; Ralston AJ; Day JP
    Kidney Int Suppl; 1986 Feb; 18():S104-7. PubMed ID: 3457985
    [No Abstract]   [Full Text] [Related]  

  • 18. [Desferrioxamine treatment of osteomalacia caused by aluminum poisoning].
    Charhon SA; Chavassieux P; Chapuy MC; Accominotti M; Traeger J; Meunier PJ
    Presse Med; 1986 Jan; 15(2):55-9. PubMed ID: 2935857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interaction of parathyroid hormone and aluminum in renal osteodystrophy.
    Slatopolsky E
    Kidney Int; 1987 Mar; 31(3):842-54. PubMed ID: 3573543
    [No Abstract]   [Full Text] [Related]  

  • 20. Aluminum-related osteomalacia in renal-failure patients.
    Vick KE; Johnson CA
    Clin Pharm; 1985; 4(4):434-9. PubMed ID: 3899471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.